Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Viaject 7 vs. Lispro in T1DM pump therapy
NCT01110746Phase 3Completed
- Sponsor
- Biodel Inc.
- Start
- Feb 2010
- Primary completion
- Jun 2010
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VIAject in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Biodel Inc. Primary endpoint: 3 hour incremental area under the glucose curve. Started Feb 2010; status: completed.
02
Drugs
VIAject
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT01110746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01110746.